Medshine Discovery Inc. has divulged amide compounds acting as epidermal growth factor receptor (EGFR) mutant inhibitors reported to be useful for the treatment of cancer.
Blueprint Medicines Corp. has disclosed EGFR (L858R/T790M/C797S triple mutant) and/or EGFR (exon 19 deletion mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Nalo Therapeutics Inc. presented the discovery and preclinical evaluation of a novel orally bioavailable and brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, NX-019, being developed as a potential therapeutic agent to treat EGFR-mutant solid tumors.
Researchers from Bayer AG presented the discovery of BAY-2927088, a new noncovalent tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in non-small-cell lung cancer (NSCLC).
Blueprint Medicines Corp. has synthesized new diazepanone-fused pyrimidines acting as epidermal growth factor receptor (EGFR) (mutant) and/or HER2 (mutant) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, eczema and psoriasis.
Dana-Farber Cancer Institute Inc. has disclosed epidermal growth factor receptor (EGFR) and mutant inhibitors reported to be useful for the treatment of cancer.
Blossomhill Therapeutics Inc. has divulged macrocyclic compounds acting as epidermal growth factor receptor (EGFR: HER1; erbB1) and EGFR mutant inhibitors reported to be useful for the treatment of cancer.
Accutar Biotechnology Inc. has identified sulfonamides acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer.
